Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

A technique for duodenitis and mast cells, which is applied in the fields of treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis and/or mast cell gastroenteritis and compositions, can solve the problem of FDA-approved treatments and more

Pending Publication Date: 2021-12-03
爱乐科斯公司
View PDF90 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] There are no FDA-approved treatments for gastritis and / or gastroenteritis with increased mast cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
  • Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
  • Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0387] Example 1: Phase 1b, open-label, dose-escalation proof-of-concept for evaluating the safety, tolerability and clinical benefit of anti-Siglec-8 antibody therapy in patients with mast cell gastritis and / or gastroenteritis research structure

[0388] Ongoing studies evaluating the efficacy and safety of anti-Siglec-8 antibodies for the treatment of patients with eosinophilic gastritis and / or gastroenteritis have identified the following subpopulation of patients, which although consistent with abdominal pain, nausea and Symptom criteria for / or diarrhea, but without the pre-requisite number of eosinophils in the gastric and / or duodenal mucosa. Instead, these patients were found to have a large number of mast cells (in most cases greater than 30 mast cells / high power field (HPF)) in the gastric and / or duodenal mucosa. Normal levels have been measured to be approximately less than 20 mast cells / HPF (Doyle et al., Am.J.Surg.Pathol. (2014) 38:832-843; Jakate et al., Arch.Path...

Embodiment 2

[0442] Example 2: Symptomatic patients suspected of having eosinophilic gastritis and / or enteritis have elevated mucosal mast cell counts in the absence of hypereosinophilia

[0443] Pathological accumulation and hyperactivation of eosinophils are implicated in a variety of chronic inflammatory diseases of the GI tract (Figure 1), including eosinophilic esophagitis (EoE), gastritis (EG), , enteritis (EEn) and colitis (collectively known as eosinophilic gastrointestinal disease, EGID). Quality of life in patients with EGID is reduced due to debilitating symptoms such as choking / dysphagia, abdominal pain, nausea, vomiting, and diarrhea.

[0444] Although the pathogenesis of EGID is historically thought to be driven by eosinophils, mast cells have also been shown to be elevated in EoE (Caldwell et al. (2014) J. Allergy Clin. Immunol. 134:1114-1124; Youngblood et al. (2019) JCI Insight 4(19)). However, the role of mast cells in EGID (especially other than EoE) has not been estab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides methods for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and / or mast cell gastroenteritis. In particular, the present disclosure provides methods for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and / or mast cell gastroenteritis through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and / or mast cell gastroenteritis.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application Serial No. 62 / 806,604, filed February 15, 2019, and U.S. Provisional Application Serial No. 62 / 925,704, filed October 24, 2019, the respective disclosures of which are incorporated by reference at It is incorporated herein in its entirety. [0003] Submission of sequence listings in ASCII text files [0004] The contents of the following submitted ASCII text file are hereby incorporated by reference in their entirety: Computer Readable Form of the Sequence Listing (CRF) (File Name: 701712001040SEQLIST.TXT, Date of Record: February 13, 2020, Size: 106KB) . technical field [0005] The present disclosure relates to the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and / or by administering antibodies that bind to human Siglec-8 and compositions comprising the same or methods for mast ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/28A61P1/04
CPCC07K16/2803A61P1/04A61K2039/505G01N33/53A61K2039/545C07K2317/41G01N33/56972G01N2800/7095G01N2800/062G01N2800/52A61P1/00G01N33/6872A61K39/3955A61K45/06C07K2317/732G01N33/5091
Inventor B·A·扬布拉德B·辛格A·坎博伊S·格林伍德H·拉斯穆森
Owner 爱乐科斯公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap